Substantia is a natural SARM-like compound under investigation, but its tissue selectivity profile is poorly understood ('terrifying'), making caution appropriate until more data emerges.

BPC-157 dosing should follow a short-term, finite protocol of 2-3 times weekly for 2-6 weeks, not continuous long-term use, and if no improvement is seen within 2-4 weeks it is unlikely to work for that particular indication.

Clinical trial data for peptides often shows flashing on-and-off benefits because many have only completed Stage 2 or Stage 3 trials without full FDA approval, creating uncertain risk-benefit profiles

Pro-insulin to insulin ratio is a marker of beta-cell dysfunction and impending pancreatic beta-cell death across all diabetes types and severe insulin resistance, even when absolute insulin levels are also elevated

Oxandrolone (Anavar), despite popular belief, causes hypothalamic-pituitary suppression (shutdown); it is not a consequence-free androgenic compound and should be used judiciously, not casually.

Pramlintide's poor adherence (three daily injections) limits practical utility compared to lifestyle interventions, making long-acting formulations strategically important for diabetic populations

GHRPs (growth hormone releasing peptides) function through two distinct mechanisms: ghrelin agonists that bind G protein-coupled receptors in the pituitary to stimulate pulsatile growth hormone release, and GHRH analogs that work on a different pituitary receptor, allowing synergistic low-dose combinations that reduce side effects while maintaining efficacy.

SARMs (Selective Androgen Receptor Modulators) are increasingly progressing through clinical trials for oncological indications, particularly ostarine (MK-2866, rebranded as Enobosarm) for triple-negative androgen receptor-positive breast cancer and prostate cancer, where they inhibit the adrenal androgen synthesis cascade without the systemic virilization of exogenous testosterone.

The optimal IGF-1 range for longevity and health is between 100-250 ng/mL, as this balances benefits of growth factor signaling against risks of tumor growth, hyperglycemia, insulin resistance (at higher levels) and sarcopenia, increased adiposity, and intramuscular triglyceride accumulation (at lower levels), with age-specific adjustments required.

GHRP-induced diabetes, which can occur with compounds like ibutamorin (MK-677), is reversible upon discontinuation and mechanistically similar to gestational diabetes, since both are caused by growth hormone-like hyperglycemic signals (gestational diabetes from human placental lactogen) rather than pancreatic beta cell failure.

Contraindications to GHRP use include active tumors (benign or malignant), family history of cancer, and risk of hyperglycemia and insulin resistance, requiring patients to undergo aggressive preventive screening with diagnostic imaging and early cancer detection protocols before initiation.

BPC-157 (body protective compound) is the only known angiogenic peptide and works by triggering the release of VEGF through capillary leakiness at injury sites, allowing plasma and growth factors to leak into tissue similar to platelet-rich plasma, which is why heat promotes healing while ice impairs it by constricting capillaries and preventing VEGF delivery.

Copper deficiency is common after bariatric surgery (gastric bypass or biliary pancreatic diversion) at approximately 10 years post-op, and board-certified bariatricians routinely screen copper levels because deficiency can cause bicytopenia (low white and red blood cells).

CJC (a GHRH analog) had its clinical trial in Brazil stopped due to a reported death, which is why Gillette personally prefers tessomorelin (Tesamorelin), which has recently received FDA approval for three different indications.

Avastin (bevacizumab), a VEGF-blocking chemotherapy drug, is prescribed because cancers overexpress VEGF and are heavily vascularized; thus, peptides like BPC-157 that increase VEGF and blood flow are contraindicated in anyone with active malignancy because they would feed tumor growth.

Bremelanotide (PT-141, Vylesi) is FDA-approved only for hypoactive sexual desire disorder in females despite working equally well in males, and it works by activating α-MSH and melanocortin receptors in the limbic system to enhance sexual arousal and spontaneous erections.

Melanocortan receptor agonists cause side effects including nausea, increased skin tanning and darkening, and loss of photo-bleaching (natural hair lightening) in blonde individuals, but do not cause downregulation or loss of efficacy with continued use.

Amylin is a peptide co-produced with insulin by pancreatic beta cells and is indicated for treatment of type 1 and type 2 diabetes; synthetic amylin (pramlintide/Symlin) has a very short half-life requiring three daily injections and is weight-negative through potentiation of insulin's glucose-lowering effects.

Insulin is described as Gillette's favorite peptide because it is life-saving, and bioidentical human insulin (as opposed to recombinant variants) preserves the native amino acid sequence required for physiological glucose homeostasis.

For approximately 98% of non-diabetic individuals with obesity and mild metabolic syndrome, semaglutide (GLP-1) is the most potent medication needed; more powerful GLP-1/GIP combination agonists (like tirzepatide/Mounjaro) and triple agonists are unnecessary and create an 'arms race' of escalation driven by pharmaceutical competition rather than clinical need.